Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

5.3%

17 terminated/withdrawn out of 318 trials

Success Rate

89.4%

+2.9% vs industry average

Late-Stage Pipeline

11%

34 trials in Phase 3/4

Results Transparency

10%

14 of 144 completed trials have results

Key Signals

49 recruiting14 with results13 terminated4 withdrawn

Enrollment Performance

Analytics

N/A
130(56.8%)
Phase 2
46(20.1%)
Phase 3
23(10.0%)
Phase 1
18(7.9%)
Phase 4
11(4.8%)
Early Phase 1
1(0.4%)
229Total
N/A(130)
Phase 2(46)
Phase 3(23)
Phase 1(18)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (318)

Showing 20 of 318 trials
NCT04116047Phase 3Active Not Recruiting

CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)

Role: lead

NCT05629702Phase 2Recruiting

ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids

Role: lead

NCT04274283Recruiting

Tessa Jowell BRAIN MATRIX - Platform Study

Role: lead

NCT04888741Phase 2Recruiting

Methods of T Cell Depletion Trial (MoTD)

Role: lead

NCT03717909Phase 2Completed

Efficacy and Safety Trial of Sodium Valproate, in Paediatric and Adult Patients With Wolfram Syndrome

Role: lead

NCT04217278Phase 2Active Not Recruiting

A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

Role: lead

NCT03821610Phase 2Active Not Recruiting

A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)

Role: lead

NCT05848765Phase 2Recruiting

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Role: lead

NCT07481435Not Yet Recruiting

TRacheostomy in DElphi for iNTensive Care' (TRiDENT)

Role: collaborator

NCT04900090Not ApplicableCompleted

Tahiti-families: Polynesian Families of Gout Patients

Role: collaborator

NCT06286709Phase 2Recruiting

FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis

Role: lead

NCT02664935Phase 2Completed

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Role: lead

NCT04116502Phase 3Recruiting

MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

Role: lead

NCT03981146Phase 2Completed

A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer

Role: lead

NCT04812886Not ApplicableCompleted

Epidemiology of Gout in French Polynesia

Role: collaborator

NCT05315570Not ApplicableCompleted

Big Data for Quality of Life in Head and Neck Cancer

Role: collaborator

NCT06447064Recruiting

Cancer Loyalty Card Study 2 (CLOCS-2)

Role: collaborator

NCT07446166Not ApplicableNot Yet Recruiting

TETANUS Antibody Detection in Saliva Study

Role: lead

NCT07443189Not ApplicableCompleted

Fitness, Ageing, and Bilingualism (FAB): The Benefits of Regular Exercise and Bilingualism for Language Abilities in Healthy Ageing.

Role: collaborator

NCT07440290Phase 2Not Yet Recruiting

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

Role: collaborator